naa a22 4500 510763081 CHVBK 20180411083146.0 cr unu---uuuuu 180411e20130101xx s 000 0 eng 10.1007/s12094-012-0882-3 doi (NATIONALLICENCE)springer-10.1007/s12094-012-0882-3 Progressive increase of glucose transporter-3 (GLUT-3) expression in estrogen-induced breast carcinogenesis [Elektronische Daten] [M. Kocdor, H. Kocdor, J. Pereira, J. Vanegas, I. Russo, J. Russo] Introduction: Increased glucose uptake and glycolysis are main metabolic characteristics of malignant cells. A family of glucose transporters (GLUTs) facilitates glucose movement across the plasma membranes in a tumor-specific manner. Glucose transporter-1 (GLUT-1), GLUT-3 and recently GLUT-12, have been previously shown in breast cancer cells and are found to be associated with poor prognosis. In addition, it has been shown that estrogen plays critical roles in GLUT regulation, however, the stage-specific GLUT regulation of mammary carcinogenesis is unclear. Methods: GLUT expression patterns were investigated in an in vitro-in vivo progressive, estrogen-induced, mammary carcinogenesis model which consisted of four cell lines, with same genetic background. In this model, different stages of tumor initiation and progression are represented, MCF-10F being the normal stage, E2 cells the transformed stage by estrogen, C5 cells, the invasive stage, and T4 cells the tumorigenic stage. In addition, loss of ductulogenesis and solid mass formation in collagen matrix and invasiveness of the cells were counted. Results: Real time PCR showed that GLUT1 expression was downregulated in MCF10F after treatment with 17β-estradiol (E2), and in the invasive cell type (C5), but not in the tumor cells (T4), which had no changes compared to MCF10F. C5 and T4 cells showed the highest rate of GLUT-3 expression. These cells were also found to be associated with loss of ductulogenesis, solid mass formation and higher invasive capacity, whereas, GLUT-12 was downregulated in C5 and T4 cells. Conclusion: Estrogen-induced malignant transformation is associated with remarkable and progressive GLUT-3 expression, GLUT-1 re-expression at further stages, as well as GLUT-12 downregulation. Federación de Sociedades Españolas de Oncología (FESEO), 2012 GLUT nationallicence Estrogen nationallicence Breast nationallicence Cancer nationallicence Kocdor M. Department of Surgery, School of Medicine, Dokuz Eylul University, 35340, Inciralti, Izmir, Turkey aut Kocdor H. Institute of Oncology, Basic Oncology, Dokuz Eylul University, 35340, Inciralti, Izmir, Turkey aut Pereira J. Breast Cancer Research Laboratory, Fox Chase Cancer Center, Philadelphia, PA, USA aut Vanegas J. Breast Cancer Research Laboratory, Fox Chase Cancer Center, Philadelphia, PA, USA aut Russo I. Breast Cancer Research Laboratory, Fox Chase Cancer Center, Philadelphia, PA, USA aut Russo J. Breast Cancer Research Laboratory, Fox Chase Cancer Center, Philadelphia, PA, USA aut Clinical and Translational Oncology Springer Milan 15/1(2013-01-01), 55-64 1699-048X 15:1<55 2013 15 12094 https://doi.org/10.1007/s12094-012-0882-3 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s12094-012-0882-3 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Kocdor M. Department of Surgery, School of Medicine, Dokuz Eylul University, 35340, Inciralti, Izmir, Turkey aut NATIONALLICENCE 700 1- Kocdor H. Institute of Oncology, Basic Oncology, Dokuz Eylul University, 35340, Inciralti, Izmir, Turkey aut NATIONALLICENCE 700 1- Pereira J. Breast Cancer Research Laboratory, Fox Chase Cancer Center, Philadelphia, PA, USA aut NATIONALLICENCE 700 1- Vanegas J. Breast Cancer Research Laboratory, Fox Chase Cancer Center, Philadelphia, PA, USA aut NATIONALLICENCE 700 1- Russo I. Breast Cancer Research Laboratory, Fox Chase Cancer Center, Philadelphia, PA, USA aut NATIONALLICENCE 700 1- Russo J. Breast Cancer Research Laboratory, Fox Chase Cancer Center, Philadelphia, PA, USA aut NATIONALLICENCE 773 0- Clinical and Translational Oncology Springer Milan 15/1(2013-01-01), 55-64 1699-048X 15:1<55 2013 15 12094 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer